The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

• DOI: 10.3389/fmed.2022.918468
• Publication Date: 2022-10-04T05:11:34Z
• Authors: Weineng Feng; Yufeng Wang; Fengming Ran; Yong Mao; Helong Zhang; Qifeng Wang; Wen Lin; Zhidong Wang; Jianli Hu; Wangjun Liao; Tao Zhang; Qian Chu; Weijie Xiong; Tienan Yi; Jiqun Yi; Shoucheng Ma; Yi Sun; Lingzhan Meng; Chunling Liu; Silang Zhou; Dengyun Zheng; Shubin Wang; Haifeng Lin; Wenzheng Fang; Jun Li; Minhui Wu
• Keywords: cancer pain; Medicine (General); pain remission; dose titration; immediate-release (IR) morphine; 3. Good health; oxycodone hydrochloride; 03 medical and health sciences; R5-920; 0302 clinical medicine; Medicine; controlled-release (CR) oxycodone

Oxycodone hydrochloride is a semisynthetic narcotic analgesic agent. This study aimed to explore optimal titration strategy of controlled-release (CR) oxycodone in patients with cancer pain.258 patients, who used regular strong opioids (morphine and CR hydrochloride) for pain across 25 three grade class hospitals China during January 15th 2017 April 30th 2017, were retrospectively studied. The divided into 4 groups according treatment regimens titrated. remission rate numeric rating scale (NRS) was recorded at 0, 12, 24, 36, 48, 60, 72 h after opioid titration. incidence adverse events (AEs) therapy also observed.12 treatment, Group B, C D significantly higher (P < 0.001) than A. For the complete rate, there significant differences among four 0.001). No difference found treatment. Multiple comparison NRS scores showed that both B varied = 0.028, P 0.05, respectively), showing superior effect over D. AEs different 0.01), most frequent A, lowest B.The rapid background effectiveness safety moderate-to-severe pain.